Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10301MR)

This product GTTS-WQ10301MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10301MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7891MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ424MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ14222MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ4150MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ10810MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ2617MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ12419MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ11163MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MDX-1333
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW